Jiangsu Kanion Pharmaceutical Co. Ltd. Class ASSE: 600557

Announcement on Receiving FDA's Approval for Clinical Trial of KYS202004A Injection

· Issued by Jiangsu Kanion Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Receiving FDA's Approval for Clinical Trial of KYS202004A Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment